A Study of the Recurrence of Hepatitis C Virus After Achieving a Sustained Virological Response
Open Access
- 30 June 2025
- journal article
- Published by Brieflands in Journal of Kermanshah University of Medical Sciences
- Vol. 29 (2)
Abstract
Background: Hepatitis C virus (HCV) infection continues to be a major public health concern. The advancement of direct-acting antivirals (DAAs) has transformed HCV therapy, making viral elimination possible. Nonetheless, experiencing a relapse following treatment continues to be a difficulty. Objectives: This research intended to evaluate the rate of HCV relapse 84 months after finishing DAA treatment. Methods: The study included 89 patients who had finished DAA therapy and achieved a sustained virologic response (SVR). These patients were monitored for as long as 84 months, with yearly follow-up appointments. Serological assessments for HIV and hepatitis B surface antigen (HBsAg) and HCV-RTPCR were performed. The average age of the participants was 23 years (± 7 years). Results: Among the 89 patients, 41 (46.07%) exhibited genotype 1 (G1), 7 (7.87%) displayed genotype 3 (G3), and 41 (46.07%) represented genotype 4 (G4). The group was made up of 52 males (58.43%) and 37 females (41.57%). A co-morbid condition, thalassemia, was observed in 10 (11.24%). No patients showed positive results for HIV or hepatitis B. During the 84-month follow-up, no relapses or reinfections were noted. Conclusions: The research validates the effectiveness of DAAs in attaining a sustained virologic response and preventing HCV recurrence. Additional research involving larger groups and extended follow-up times is necessary to confirm these results.Keywords
This publication has 10 references indexed in Scilit:
- Hepatitis C: recent advances and practical managementFrontline Gastroenterology, 2023
- Reinfección por virus de la hepatitis C: revisión de tema y presentación de un casoRevista Colombiana de Gastroenterología, 2022
- The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysisLiver International, 2021
- Impact of the Covid-19 pandemic on the elimination of hepatitis C virus in Duhok, Kurdistan, Iraq: A retrospective cross-sectional studyJournal of Family Medicine and Primary Care, 2020
- Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment optionsVirusDisease, 2018
- The negative impact of HBV/HCV coinfection on cirrhosis and its consequencesAlimentary Pharmacology & Therapeutics, 2017
- Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral EraCurrent Epidemiology Reports, 2017
- The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with HaemoglobinopathyMediterranean Journal of Hematology and Infectious Diseases, 2016
- Successful Treatment of Hepatitis C Virus Genotype 4 in Renal Transplant Recipients With Direct‐Acting Antiviral AgentsAmerican Journal of Transplantation, 2016
- Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2016